Clinical Trial Update: Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that Lisaftoclax (APG-2575) is being studied as a single agent and in combination for relapsed/refractory acute myeloid leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myeloid Malignancies

Drugs mentioned

• Lisaftoclax (APG-2575)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | Phase 1, Phase 2 | Status: RECRUITING